Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2023.08.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
VA-ECMO Supported Aspiration Thrombectomy for High-Risk PE: A Single-Center Experience.
J Soc Cardiovasc Angiogr Interv
December 2024
Division of Cardiovascular Disease, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
[A case of the "6+2" phenomenon on electrocardiogram caused by acute pulmonary embolism].
Zhonghua Xin Xue Guan Bing Za Zhi
January 2025
Department of Cardiology, Ningbo Medical Center LiHuili Hospital, Ningbo315000, China.
Post-operative complications associated with the pre-operative use of Aspirin in patients undergoing surgery for hip or femoral fracture: a meta-analysis.
Eur J Trauma Emerg Surg
January 2025
Department of Orthopedics, Huanggang Central Hospital of Yangtze University, Huanggang, 438000, Hubei, People's Republic of China.
Background: The number of patients with hip and femoral fractures is increasing and is expected to further increase in upcoming years due to the ageing population and the life expectancy of the general population. In this analysis, we aimed to systematically assess the post-operative complications associated with the pre-operative use of Aspirin in patients undergoing surgery for hip or femoral fracture.
Methods: Common online databases: Google Scholar, Web of Science, MEDLINE, Cochrane database, EMBASE ( www.
Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer (NSCLC) after progression on prior osimertinib.
Ann Oncol
January 2025
David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address:
Background: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression.
View Article and Find Full Text PDFA review of venous thromboembolism for the hospitalist.
Postgrad Med
January 2025
Lankenau Medical Center, Wynnewood, PA, USA.
Venous thromboembolism (VTE), consisting of both deep vein thrombosis (DVT) and pulmonary embolism (PE), is an extremely common condition both in the United States and worldwide. Not only is the diagnosis associated with significant morbidity and mortality for patients, but also it imposes a deleterious financial burden on the US healthcare system. Diagnosis may be challenging due to variability in clinical presentation and requires a sequential workup including assessment of clinical pretest probability for VTE, D-dimer testing, and imaging.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!